Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Corroborated by 2 sources from 2 publishers
globalcrime2d ago
TL;DR
Jun.
Sources
1
Business Insider Markets News
https://markets.businessinsider.com/news/stocks/agios-showcases-rise-up-phase-3-results-at-eha-2026-plenary-session-reinforcing-strong-anti-hemolytic-profile-of-mitapivat-in-sickle-cell-disease-1036247511
2d ago
2
Investing.com News
https://www.investing.com/news/company-news/agios-presents-detailed-mitapivat-trial-results-for-sickle-cell-93CH-4741036
2d ago